ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

itepekimab

Also written as “Itepekimab (SAR440340)”, “REGN3500” and “Itepekimab SAR440340”.

Its studies are mostly in Nasal Polyps · Pulmonary Disease, Chronic Obstructive · Asthma · Dermatitis, Atopic · Bronchiectasis, led by 2 companies.

Drug pageItepekimab: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 30, 202017 company-led studies, 3 open or runningNext primary completion: Feb 17, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofiits history only123 open or runningphase 3since Dec 30, 2020Dec 15, 2017Feb 17, 2027phase 3 · NCT07424144
Regeneron Pharmaceuticals50 open or runningphase 2since Nov 7, 2018Oct 25, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Regeneron Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 25, 2016First study: phase 1 study in Healthy VolunteersFirst studyNCT02958436 · 40 enrolled · Belgium
  2. Dec 19, 2016Phase 1 study in AsthmaNCT02999711 · 23 enrolled · United Kingdom
  3. Apr 4, 2017Phase 1 study in AsthmaNCT03112577 · 32 enrolled · United States, United Kingdom
  4. Nov 7, 20182 phase 2 studies in Dermatitis, AtopicNCT03736967, NCT03738423
  5. Dec 9, 2019Named itepekimabINNProposed as its International Nonproprietary Name in WHO's List 122 · before, REGN3500, SAR440340

TargetBeta

IL33 →read by rule
“Interleukin-33 inhibitor”ChEMBL 37, by rule

Other programs on IL33

ProgramCompanyFurthest phaseStudies
GSK3862995BGlaxoSmithKlinephase 25
ompekimigPfizerphase 23
HXN-1013ruleHelixon Biotechnology (Suzhou)phase 11
HY6725ruleNewsoara Biopharmaphase 11

Studies

All 5 Regeneron Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03738423Dermatitis, Atopic · United States, Australia, Canada and more2TerminatedMar 13, 2020129
NCT03736967Dermatitis, Atopic · United States, Belgium, Czechia and more2TerminatedMar 13, 2020206
NCT03112577Asthma · United States, United Kingdom1CompletedMar 20, 201932
NCT02999711Asthma · United Kingdom1CompletedAug 30, 201823
NCT02958436Healthy Volunteers · Belgium1CompletedJun 18, 201740

How it is read

Names in the registry

  • “Itepekimab (SAR440340)”, 7 entries
  • “REGN3500”, 5 entries
  • “Itepekimab SAR440340”, 3 entries
  • “SAR440340”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.